Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
DarioHealth ( (DRIO) ) just unveiled an announcement.
On November 5, 2025, DarioHealth Corp. entered into a Credit Agreement Amendment with Callodine Commercial Finance, LLC, acting as agent and lender, alongside other financial institutions. This amendment is a significant step for DarioHealth, potentially impacting its financial operations and strategic positioning in the healthcare technology sector.
The most recent analyst rating on (DRIO) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
Spark’s Take on DRIO Stock
According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.
DarioHealth’s overall stock score is primarily impacted by its financial performance challenges, including ongoing losses and negative cash flow. While technical indicators show some potential, the valuation remains problematic due to a negative P/E ratio. The company’s strategic initiatives and client acquisition provide some optimism, but significant risks persist.
To see Spark’s full report on DRIO stock, click here.
More about DarioHealth
Average Trading Volume: 68,047
Technical Sentiment Signal: Strong Sell
Current Market Cap: $84.6M
For a thorough assessment of DRIO stock, go to TipRanks’ Stock Analysis page.